GlassScriptPhysician profile
Margaret M Mack
NPI 1962618686
$5,939.99
in general payments reported to CMS, 2019-2025
17 companies · $2,534 in 2025
The $2,534 reported for 2025 was more than what 95% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
See the full distribution for Psychiatric/Mental Health, Adult (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $1,057 · 2023: $893 · 2024: $1,324 · 2025: $2,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,268 · Travel and Lodging: $348 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,268.46 |
| Travel and Lodging | $347.96 |
| Education | $133.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,171.67 | 2022-2025 | Caplyta |
| Abbvie INC. | $863.04 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $553.78 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $467.92 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Bausch Health US, LLC | $446.16 | 2021-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $440.18 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $390.57 | 2024-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $347.96 | 2024 | |
| Alkermes, INC. | $290.11 | 2022-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $289.11 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $192.15 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $174.99 | 2022-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $99.83 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $81.01 | 2022-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $80.21 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.30 | 2024 | Invega |
| Almatica Pharma LLC | $25.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.